From: The cost-utility of early use of high-flow nasal cannula in bronchiolitis
Model input | Base case value | SA range for one-way sensitivity analyses | Source |
---|---|---|---|
Probability | |||
Hospitalization | 0,25 | 0,01-0,41 | (21) |
PICU, given hospitalization | 0,07 | 0,06-0,18 | (20) |
Mortality, given PICU admission | 0,009 | 0,001–0,06 | (16) |
Acute complications, given hospitalization | 0,13 | 0,10–0,20 | (15) |
Acute complications, given PICU admission | 0,15 | 0,15-0,53 | (23) |
Treatment failure in control group | 0.22 | 0.19–0.29 | (25) |
Utility | |||
No hospitalization | 0,95 | 1,00–0,76 | (31–34) |
Hospitalization without acute complications | 0,88 | 1,00–0,70 | (35, 36) |
Hospitalization with acute complications | 0,59 | 0,70–0,47 | (35, 36) |
PICU without acute complications | 0,73 | 0,87-0,58 | (35, 36) |
PICU with acute complications | 0,51 | 0,60–0,40 | (35, 36) |
HFNC effectiveness | |||
Relative risk of reduction of treatment failure | 0,57 | 0,45-0,72 | (25) |